These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22190063)

  • 21. The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
    Wang T; Li H; Wang F; Sun L; Yu L
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1679-1686. PubMed ID: 34164723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
    Xie X; Ma YT; Yang YN; Li XM; Ma X; Fu ZY; Zheng YY; Chen BD; Liu F
    PLoS One; 2013; 8(3):e59344. PubMed ID: 23555019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomics of clopidogrel: evidence and perspectives.
    Yin T; Miyata T
    Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic determinants of platelet response to clopidogrel.
    Kubica A; Kozinski M; Grzesk G; Fabiszak T; Navarese EP; Goch A
    J Thromb Thrombolysis; 2011 Nov; 32(4):459-66. PubMed ID: 21706290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
    Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
    JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.
    Santos PC; Soares RA; Santos DB; Nascimento RM; Coelho GL; Nicolau JC; Mill JG; Krieger JE; Pereira AC
    BMC Med Genet; 2011 Jan; 12():13. PubMed ID: 21247447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting.
    Correll M; Johnson CK; Ferrari G; Brizzio M; Mak AW; Quackenbush J; Shaw RE; Zapolanski A; Grau JB
    Genomics; 2013 Jun; 101(6):313-7. PubMed ID: 23462555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.
    Rideg O; Komócsi A; Magyarlaki T; Tokés-Füzesi M; Miseta A; Kovács GL; Aradi D
    Pharmacogenomics; 2011 Sep; 12(9):1269-80. PubMed ID: 21806387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort.
    Melin K; Moon JY; Qi Q; Hernandez-Suarez DF; Duconge J; Hua S; Gonzalez S; Zeng D; Kaplan RC
    Pharmacogenomics; 2019 Jan; 20(2):75-83. PubMed ID: 30520344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
    Jin B; Ni HC; Shen W; Li J; Shi HM; Li Y
    Mol Biol Rep; 2011 Mar; 38(3):1697-702. PubMed ID: 20845077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
    Kim HS; Chang K; Koh YS; Park MW; Choi YS; Park CS; Oh M; Kim EY; Shon JH; Shin JG; Seung KB
    Circ Cardiovasc Genet; 2013 Oct; 6(5):514-21. PubMed ID: 24019397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
    Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
    Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?
    Singh M; Shah T; Adigopula S; Molnar J; Ahmed A; Khosla S; Arora R
    Indian Heart J; 2012; 64(4):341-52. PubMed ID: 22929815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the pharmacogenetics of clopidogrel.
    Cuisset T; Morange PE; Alessi MC
    Hum Genet; 2012 May; 131(5):653-64. PubMed ID: 22207144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.